Pancreatic islet autoantibodies as predictors of type 1 diabetes in the Diabetes Prevention Trial-Type 1
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: There is limited information from large-scale prospective studies regarding the prediction of type 1 diabetes by specific types of pancreatic islet autoantibodies, either alone or in combination. Thus, we studied the extent to which specific autoantibodies are predictive of type 1 diabetes. RESEARCH DESIGN AND METHODS: Two cohorts were derived from the first screening for islet cell autoantibodies (ICAs) in the Diabetes Prevention Trial-Type 1 (DPT-1). Autoantibodies to GAD 65 (GAD65), insulinoma-associated antigen-2 (ICA512), and insulin (micro-IAA [mIAA]) were also measured. Participants were followed for the occurrence of type 1 diabetes. One cohort (Questionnaire) included those who did not enter the DPT-1 trials, but responded to questionnaires (n = 28,507, 2.4% ICA(+)). The other cohort (Trials) included DPT-1 participants (n = 528, 83.3% ICA(+)). RESULTS: In both cohorts autoantibody number was highly predictive of type 1 diabetes (P < 0.001). The Questionnaire cohort was used to assess prediction according to the type of autoantibody. As single autoantibodies, ICA (3.9%), GAD65 (4.4%), and ICA512 (4.6%) were similarly predictive of type 1 diabetes in proportional hazards models (P < 0.001 for all). However, no subjects with mIAA as single autoantibodies developed type 1 diabetes. As second autoantibodies, all except mIAA added significantly (P < 0.001) to the prediction of type 1 diabetes. Within the positive range, GAD65 and ICA autoantibody titers were predictive of type 1 diabetes. CONCLUSIONS: The data indicate that the number of autoantibodies is predictive of type 1 diabetes. However, mIAA is less predictive of type 1 diabetes than other autoantibodies. Autoantibody number, type of autoantibody, and autoantibody titer must be carefully considered in planning prevention trials for type 1 diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Indeed, the risk of type 1 diabetes increases as the number of relevant autoantibodies detected increases (55,74,75).”
From 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2024 (2024) · cites this paper as [74]
The cited source says what the claim attributes to it.
In the citing paper
“Indeed, the risk of type 1 diabetes increases as the number of relevant autoantibodies detected increases (53,74,75).”
From 2. Diagnosis and classification of diabetes: standards of care in diabetes-2025 (2025) · cites this paper as [74]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Christakis, D., Richards, J. A., Zimmerman, F. J., Garrison, M. M., Xu, D., & Yapanel, U. H. (2009) · Cited by 2,289
ISLET-CELL ANTIBODIES IN DIABETES MELLITUS WITH AUTOIMMUNE POLYENDOCRINE DEFICIENCIES
Bottazzo, G., Florin-Christensen, A., & Doniach, D. (1974) · The Lancet · doi:10.1016/s0140-6736(74)90140-8 · Cited by 1,469 · cited 2×
“The number shown for each curve (1, 2) indicates the number of autoantibodies.”
BackgroundInsulin antibodies in insulin-dependent diabetics before insulin treatment
Palmer, J. P., Asplin, C. M., Clemons, P., Lyen, K., Tatpati, O., Raghu, P. K., & Paquette, T. L. (1983) · Science · doi:10.1126/science.6362005 · Cited by 1,078
Self-citationEffects of insulin in relatives of patients with type 1 diabetes mellitus
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012350 · Cited by 836
Termination of Pregnancy on Psychiatric Grounds
(1964) · The Lancet · doi:10.1016/s0140-6736(64)92746-1 · Cited by 681
Effects of Oral Insulin in Relatives of Patients With Type 1 Diabetes
The Diabetes Prevention Trial-Type 1 Study Group (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1068 · Cited by 668
Keele, G. (1973) · The Lancet · doi:10.1016/s0140-6736(73)91022-2 · Cited by 499
EVIDENCE FOR A LONG PREDIABETIC PERIOD IN TYPE I (INSULIN-DEPENDENT) DIABETES MELLITUS
Gorsuch, A. N., Lister, J., Dean, B. M., Spencer, K. M., Mcnally, J. M., Bottazzo, G. F., & Cudworth, A. G. (1981) · The Lancet · doi:10.1016/s0140-6736(81)92795-1 · Cited by 480
Grubin, C. E., Daniels, T., Toivola, B., Landin-Olsson, M., Hagopian, W. A., Li, L., Karlsen, A. E., Boel, E., Michelsen, B., & Lernmark, �. (1994) · Diabetologia · doi:10.1007/bf00408469 · Cited by 415 · cited 1×
“Labeled recombinant GAD65 and ICA512 autoantibodies were produced by in vitro transcription/ translation with differential labeling ([(3)H]GAD65 and [(35)S]ICA512) (8,13).”
MethodBingley, P. J., Christie, M. R., Bonifacio, E., Bonfanti, R., Shattock, M., Fonte, M.-T., Bottazzo, G.-F., & Gale, E. A. M. (1994) · Diabetes · doi:10.2337/diab.43.11.1304 · Cited by 389
Cited by
Items 101–200 of 269
Smith, M. J., Rihanek, M., Wasserfall, C. H., Mathews, C. E., Atkinson, M. A., Gottlieb, P. A., & Cambier, J. C. (2018) · Diabetes · doi:10.2337/db17-0937 · Cited by 39
Steck, A. K., Fouts, A., Miao, D., Zhao, Z., Dong, F., Sosenko, J. M., Gottlieb, P. A., Rewers, M., Yu, L., & and the TrialNet Study Group (2016) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2015.0316 · Cited by 41
Self-citationChurch, D., Cardoso, L., Bradbury, S., Clarke, C., Stears, A. J., Dover, A. R., Halsall, D. J., & Semple, R. K. (2016) · Clinical Endocrinology · doi:10.1111/cen.13179 · Cited by 37
Gabbay, M. A. L., Sato, M. N., Duarte, A. J. S., & Dib, S. A. (2011) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2011.04538.x · Cited by 36
Characterising the age-dependent effects of risk factors on type 1 diabetes progression
So, M., O’Rourke, C., Ylescupidez, A., Bahnson, H. T., Steck, A. K., Wentworth, J. M., Bruggeman, B., Lord, S. M., Greenbaum, C. J., & Speake, C. (2022) · Diabetologia · doi:10.1007/s00125-021-05647-5 · Cited by 38
The Development, Validation, and Utility of the Diabetes Prevention Trial-Type 1 Risk Score (DPTRS)
Groups, T. D. T. 1. T. A. D. P. T.-T. 1. S., Sosenko, J. M., Skyler, J. S., & Palmer, J. P. (2015) · Current Diabetes Reports · doi:10.1007/s11892-015-0626-1 · Cited by 31
Self-citationPredicting progression to diabetes in islet autoantibody positive children
Steck, A. K., Dong, F., Frohnert, B. I., Waugh, K., Hoffman, M., Norris, J. M., & Rewers, M. (2018) · Journal of Autoimmunity · doi:10.1016/j.jaut.2018.01.006 · Cited by 33
Wang, Y., Qin, Y., Wang, X., Zhang, L., Wang, J., Xu, X., Chen, H., Hsu, H.-T., & Zhang, M. (2020) · Clinical & Experimental Immunology · doi:10.1111/cei.13408 · Cited by 33
Type 1 diabetes mellitus in pediatric age group: A rising endemic
Pasi, R., & Ravi, K. S. (2022) · Journal of Family Medicine and Primary Care · doi:10.4103/jfmpc.jfmpc_975_21 · Cited by 33
Citrullination: A modification important in the pathogenesis of autoimmune diseases
Zhu, D., Wei, S., Jiang, Z., Zhou, H.-P., & Wang, S. (2022) · Clinical Immunology · doi:10.1016/j.clim.2022.109134 · Cited by 33
Genetic and diabetic auto-antibody markers in Saudi children with type 1 diabetes
Manan, H., Angham, A. M., & Awadalla, S. A. (2010) · Human Immunology · doi:10.1016/j.humimm.2010.09.008 · Cited by 35
Masala, S., Zedda, M. A., Cossu, D., Ripoli, C., Palermo, M., & Sechi, L. A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0063371 · Cited by 33
“preceding T1D clinical onset, autoantibodies (aAbs) directed to islets antigens such as insulin, glutamic acid decarboxylase (GAD65), insulinoma associated protein-2 and zinc transporter 8 (Znt8) may be detectable for months up to years before disease onset [2], and progressively wane after diagnosis [3].”
BackgroundREDONDO, M. J., Sosenko, J. M., Libman, I. M., MCVEAN, J. J. F., Tosur, M., Atkinson, M. A., BECKER, D. J., & Geyer, S. M. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz296 · Cited by 31
Self-citationFouts, A., Pyle, L. L., Yu, L., Miao, D., Michels, A. W., Krischer, J. P., Sosenko, J. M., Gottlieb, P. A., Steck, A. K., & the Type 1 Diabetes TrialNet Study Group (2016) · Diabetes Care · doi:10.2337/dc16-0302 · Cited by 31
Self-citationKornete, M., Mason, E. S., & Piccirillo, C. A. (2013) · Frontiers in Endocrinology · doi:10.3389/fendo.2013.00076 · Cited by 33
“Notable T1D auto-antigens identified include insulin, GAD65 (glutamic acid decarboxylase, 65 kDa isoform), IA2 (insulin auto-antigen 2), and zinc transporter 8 (ZNT8) (Sabbah et al., 1999; Orban et al., 2009).”
Gut microbiome in type 1 diabetes: the immunological perspective
Rampanelli, E., & Nieuwdorp, M. (2022) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2023.2150612 · Cited by 32
Role of immune system modulation in prevention of type 1 diabetes mellitus
Hassan, G. A., Sliem, H. A., Ellethy, A. T., & Salama, M.-S. (2012) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.102989 · Cited by 31
Occhipinti, M., Lampasona, V., Vistoli, F., Bazzigaluppi, E., Scavini, M., Boggi, U., Marchetti, P., & Bosi, E. (2011) · Transplantation · doi:10.1097/tp.0b013e31822ae65f · Cited by 31
“, family members of patients with type 1 diabetes) where their predictive value is associated with the titer and number of positive autoantibodies (9, 10).”
BackgroundUnderstanding Why Some Women with a History of Gestational Diabetes Do Not Get Tested for Diabetes
Paez, K., Eggleston, E., Griffey, S., Farrar, B. D., Smith, J., Thompson, J. L., & Gillman, M. W. (2014) · Women s Health Issues · doi:10.1016/j.whi.2014.04.008 · Cited by 29
Endotypes in T1D: B lymphocytes and early onset
Smith, M. J., Cambier, J. C., & Gottlieb, P. A. (2020) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000547 · Cited by 29
Immune perturbations in human pancreas lymphatic tissues prior to and after type 1 diabetes onset
Golden, G. J., Wu, V. H., Hamilton, J. T., Amses, K. R., Shapiro, M. R., Japp, A. S., Liu, C., Pampena, M. B., Kuri-Cervantes, L., Knox, J. J., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-59626-0 · Cited by 29
“Furthermore, as not all single AAb+ donors develop T1D 2,93 , additional studies of pLNs from donors with >1AAb+ across a range of AAb speci fi cities will be necessary to de fi ne immunological associations with pre-T1D.”
Extrapancreatic Autoantibody Profiles in Type I Diabetes
Burbelo, P. D., Lebovitz, E. E., Bren, K. E., Bayat, A., Paviol, S., Wenzlau, J. M., Barriga, K. J., Rewers, M., Harlan, D. M., & Iadarola, M. J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0045216 · Cited by 28
“The most reliable factors for identifying future onset of T1D include autoantibody seropositivity against multiple islet antigens, high antibody titers, young age at seroconversion, and persistent autoantibodies against insulin [4,5,6,7,8,9,10,11].”
BackgroundThe role of B cells in the pathogenesis of type 1 diabetes
Wang, Y., Li, R., Huang, Y., Chen, H., Nie, H., Liu, L., Zou, X., Zhong, J., Zheng, B., & Gong, Q. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1450366 · Cited by 28
Sosenko, J. M., Yu, L., Skyler, J. S., Krischer, J. P., Gottlieb, P. A., Boulware, D. C., Miao, D., Palmer, J. P., & Steck, A. K. (2017) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2016.0243 · Cited by 28
“It would appear that these individuals deserve systematic surveillance for progression to T1D.”
BackgroundSelf-citationKaraoğlan, M., & Nacarkahya, G. (2020) · Journal of Diabetes · doi:10.1111/1753-0407.13097 · Cited by 27
“All three antibodies (anti-GAD, anti-ICA and anti-IA) can be found to be seropositive up to 25%-80% in T1DM patients.(17) However, their seropositivity in T2DM patients poses challenges in differential diagnosis.”
BackgroundAntigen-specific immunotherapies in type 1 diabetes
Zhang, X., Dong, Y., Liu, D., Yang, L., Xu, J., & Wang, Q. (2022) · Journal of Trace Elements in Medicine and Biology · doi:10.1016/j.jtemb.2022.127040 · Cited by 26
Frohnert, B. I., Ghalwash, M. F., Li, Y., Ng, K., Dunne, J. L., Lundgren, M., Hagopian, W., Lou, O., Winkler, C., Toppari, J., et al. (2023) · Diabetes Care · doi:10.2337/dc22-1960 · Cited by 27
Self-citationIA-2 autoantibody affinity in children at risk for type 1 diabetes
Krause, S., Chmiel, R., Bonifacio, E. E., Scholz, M., Powell, M. J., Furmaniak, J., Smith, B. R., Ziegler, A., & Achenbach, P. (2012) · Clinical Immunology · doi:10.1016/j.clim.2012.09.010 · Cited by 27
Targeted immune interventions for type 1 diabetes
Rigby, M. R., & Ehlers, M. R. (2014) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000075 · Cited by 25
“Nevertheless, the presence of autoantibodies significantly predates the clinical onset of disease, suggesting they may play a role in disease progression [10,16,19].”
Posgai, A. L., Wasserfall, C. H., Kwon, K., Daniell, H., Schatz, D., & Atkinson, M. A. (2017) · Scientific Reports · doi:10.1038/srep42372 · Cited by 23
Self-citationPositive evidence for vitamin A role in prevention of type 1 diabetes
Yosaee, S., Fakhrabadi, M. A., & Shidfar, F. (2016) · World Journal of Diabetes · doi:10.4239/wjd.v7.i9.177 · Cited by 23
Wang, Y., Yuan, W., Guo, H., & Jiang, Y. (2014) · Autoimmunity · doi:10.3109/08916934.2014.990629 · Cited by 27
The Benefits of Using Genetic Information to Design Prevention Trials
Hu, Y., Li, L., Ehm, M. G., Bing, N., Song, K. S., Nelson, M. R., Talmud, P. J., Hingorani, A. D., Meena Kumari, B., Mika Kivimaki, B., et al. (2013) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2013.03.003 · Cited by 21
Strollo, R., Vinci, C., Napoli, N., Fioriti, E., Maddaloni, E., Åkerman, L., Casas, R., Pozzilli, P., Ludvigsson, J., & Nissim, A. (2019) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3132 · Cited by 22
Staging the progression to type 1 diabetes with prediagnostic markers
Sosenko, J. M. (2016) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000267 · Cited by 25
Self-citationNon-HLA type 1 diabetes genes modulate disease risk together with HLA-DQ and islet autoantibodies
Maziarz, M., Hagopian, W., Palmer, J. P., Sanjeevi, C. B., Kockum, I. S., Breslow, N. E., Lernmark, Å., Graham, J., MacNeney, B., Arnqvist, H. J., et al. (2015) · Genes and Immunity · doi:10.1038/gene.2015.43 · Cited by 23
“The length of the second step may be dependent not only on the number of islet autoantibodies 8, 12, 13 but also on HLA and non-HLA genes 14-16 as well as environmental factors 17 .”
Self-citationChéramy, M., Hampe, C. S., Ludvigsson, J., & Casas, R. (2012) · Clinical & Experimental Immunology · doi:10.1111/cei.12026 · Cited by 20
“Approximately 70-80% of newly diagnosed T1D patients have detectable GADA in serum [13], and the presence of persistent GADA together with other T1D-associated autoantibodies is a strong predictor for progression to disease in healthy individuals [14-16].”
Khan, W. A. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.68834 · Cited by 24
Varvel, S. A., Vörös, S., Thiselton, D. L., Pottala, J. V., Dall, T., Warnick, G. R., McConnell, J. P., Ghaedi, L., Sasinowski, M., & Graham, T. E. (2014) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-014-9577-1 · Cited by 20
“It is now possible to assess insulin resistance [18–34], beta cell function [35–41], and glycemic control [10–12, 42–44] using peripheral blood-based biomarkers [45–47].”
BackgroundAnti-Insulin Immune Responses Are Detectable in Dogs with Spontaneous Diabetes
Kim, J. H., Furrow, E., Ritt, M. G., Utz, P. J., Robinson, W. H., Yu, L., Eckert, A. L., Stuebner, K., O’Brien, T. D., Steinman, L., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0152397 · Cited by 19
Self-citationVaccination against type 1 diabetes
Larsson, H. E., & Lernmark, Å. (2011) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2011.02386.x · Cited by 19
Andersson, C., Carlsson, A., Cilio, C., Cedervall, E., Ivarsson, S.-A., Jónsdóttir, B., Jönsson, B., Larsson, K., Neiderud, J., Lernmark, Å., et al. (2013) · Pediatric Diabetes · doi:10.1111/pedi.12023 · Cited by 18
“immunological markers of T1D risk (7, 8).”
BackgroundSelf-citationThyroid profile and autoantibodies in Type 1 diabetes subjects: A perspective from Eastern India
Sanyal, D., Majumder, A., Chaudhuri, S. R., & Chatterjee, S. (2016) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.195998 · Cited by 19
Krischer, J. P., Müller, S., You, L., Achenbach, P., Bazzigaluppi, E., Brigatti, C., Lampasona, V., Mathew, A., Robinson, P. V., Seftel, D., et al. (2025) · Diabetes · doi:10.2337/db24-0814 · Cited by 17
Self-citationType 1 Diabetes: Disease Stratification
Insel, R. A., Dutta, S., & Hedrick, J. A. (2017) · Biomedicine Hub · doi:10.1159/000481131 · Cited by 18
Islet Autoantibody Detection by Electrochemiluminescence (ECL) Assay
Yu, L. (2015) · Methods in molecular biology · doi:10.1007/7651_2015_296 · Cited by 17
Self-citationDai, L.-Y., Feng, C.-M., Liu, J., Zheng, C.-H., Yu, J., & Hou, M.-X. (2017) · Complexity · doi:10.1155/2017/4216797 · Cited by 16
Liu, B., Hu, Y., Wu, Q., Zeng, Y., Xiao, Y., Zeng, X., Fang, Y., Zhang, L., Li, T., & Yu, H. (2020) · Journal of Diabetes Research · doi:10.1155/2020/4631290 · Cited by 16
“B cells play key roles in the production of cytokines and antibodies in humans and mice [10, 11] and were found to regulate inflammation in patients with DM [12–15].”
BackgroundTriolo, T. M., Pyle, L. L., Seligova, S., Yu, L., Simmons, K. M., Gottlieb, P. A., Evans‐Molina, C., & Steck, A. K. (2021) · Journal of Translational Autoimmunity · doi:10.1016/j.jtauto.2021.100089 · Cited by 16
Self-citationTime to reframe the disease staging system for type 1 diabetes
Jacobsen, L. M., Atkinson, M. A., Sosenko, J. M., & Gitelman, S. E. (2024) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00239-0 · Cited by 16
Self-citationHaller, M. J., Atkinson, M. A., Wasserfall, C. H., Brusko, T. M., Mathews, C. E., Hulme, M. A., Cintrón, M., Shuster, J. J., McGrail, K., Posgai, A. L., et al. (2015) · Clinical & Experimental Immunology · doi:10.1111/cei.12731 · Cited by 15
Self-citationXiao, Y., Deng, C., & Zhou, Z. (2021) · Journal of Diabetes Research · doi:10.1155/2021/6581213 · Cited by 15
Åkerman, L., Ludvigsson, J., Swartling, U., & Casas, R. (2017) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2900 · Cited by 15
Novel Biomarkers in Type 1 Diabetes
Jin, Y., & She, J. (2012) · The Review of Diabetic Studies · doi:10.1900/rds.2012.9.224 · Cited by 17
“In subjects with two autoantibodies the risk keeps rising to 16%, and jumps to 40% and 50% in subjects with three and four autoantibodies, respectively [81].”
BackgroundChen, C. H. A. O., Huang, G., Li, X., Yang, L., Lin, J., Jin, P., Luo, S., Zhang, Y., Pan, L., & Zhou, Z. (2013) · Chinese Medical Journal · doi:10.3760/cma.j.issn.0366-6999.20130841 · Cited by 15
Association of High-Affinity Autoantibodies With Type 1 Diabetes High-Risk HLA Haplotypes
Triolo, T. M., Pyle, L. L., BRONCUCIA, H. C., Armstrong, T., Yu, L., Gottlieb, P. A., & Steck, A. K. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab853 · Cited by 14
Self-citationA unique CD8+ T lymphocyte signature in pediatric type 1 diabetes
Hamel, Y., Mauvais, F., Pham, H., Kratzer, R., Marchi, C., Barilleau, É., Waeckel-Énée, E., Arnoux, J., Hartemann, A., Cordier, C., et al. (2016) · Journal of Autoimmunity · doi:10.1016/j.jaut.2016.06.003 · Cited by 16
Islet Autoantibody Detection by Electrochemiluminescence (ECL) Assay
Gu, Y., Zhao, Z., High, H., Yang, T., & Yu, L. (2017) · Journal of Clinical & Cellular Immunology · doi:10.4172/2155-9899.1000531 · Cited by 14
Self-citationβ cell responses to inflammation
Usmani‐Brown, S., Perdigoto, A. L., Lavoie, N., Clark, P. L., Korah, M. M., Rui, J., Betancur, G., & Herold, K. C. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.06.013 · Cited by 14
Balakrishnan, S., Kumar, P., & Prabhakar, B. S. (2020) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2020.140478 · Cited by 14
Petruželková, L., Dušátková, P., Cinek, O., Šumník, Z., Průhová, Š., Hradský, O., Včeláková, J., Lebl, J., & Koloušková, S. (2015) · Diabetic Medicine · doi:10.1111/dme.13043 · Cited by 15
Type 1 Diabetes: A Disorder of the Exocrine and Endocrine Pancreas
Bruggeman, B., & Schatz, D. (2023) · Journal of Cellular Immunology · doi:10.33696/immunology.5.177 · Cited by 13
“Exocrine serum, stool, or imaging markers could be integrated into existing T1D Risk Scores in combination with other already established biomarkers to further refine risk prediction [52,53].”
BackgroundSelf-citationFrom Prediction to Prevention: The Intricacies of Islet Autoantibodies in Type 1 Diabetes
Khine, A., & Quandt, Z. (2025) · Current Diabetes Reports · doi:10.1007/s11892-025-01595-1 · Cited by 14
“In relatives of individuals with T1D, the DPT-1 study found that the 5-year risk of developing clinical T1D was 25% for two autoantibodies, 40% for three autoantibodies, and 50% for four autoantibodies [17].”
Wilson, C., Elizer, S. K., Marshall, A. F., Stocks, B. T., & Moore, D. J. (2015) · Journal of Diabetes · doi:10.1111/1753-0407.12263 · Cited by 13
“by years or decades.(1,2) Studies in mouse models of diabetes and in patients with T1D have indicated the efficacy of B lymphocyte-depleting therapy in attenuating disease.”
BackgroundAntigen-based vs. systemic immunomodulation in type 1 diabetes: The pros and cons
Robert, S., Korf, H., Gysemans, C. A., & Mathieu, C. (2013) · Islets · doi:10.4161/isl.24785 · Cited by 16
Rich, S. S., & CONCANNON, P. J. (2015) · Diabetes Care · doi:10.2337/dcs15-2001 · Cited by 13
Characterizing Subgroups of Type 1 Diabetes
Skyler, J. S. (2014) · Diabetes · doi:10.2337/db14-1160 · Cited by 14
Self-citationStratifying risk for onset of type 1 diabetes using islet autoantibody trajectory clustering
Mistry, S., Gouripeddi, R., Raman, V. S., & Facelli, J. C. (2022) · Diabetologia · doi:10.1007/s00125-022-05843-x · Cited by 12
Qiu, Y.-H., Deng, F., Tang, Z., Jiang, Z., & Lei, S. (2015) · Human Immunology · doi:10.1016/j.humimm.2015.09.033 · Cited by 12
Sosenko, J. M., Cuthbertson, D. D., Sims, E. K., Ismail, H. M., Nathan, B. M., Jacobsen, L. M., Atkinson, M. A., Evans‐Molina, C., Herold, K. C., Skyler, J. S., et al. (2023) · Diabetes Care · doi:10.2337/dc22-2236 · Cited by 12
Self-citationOakey, H., Giles, L. C., Thomson, R. L., Cao, K. L., Ashwood, P., Brown, J. D., Knight, E. J., Barry, S. C., Craig, M. E., Colman, P. G., et al. (2023) · Annals of Medicine · doi:10.1080/07853890.2023.2198255 · Cited by 12
“While the persistent IA outcome includes single IA and multiple IA, children as young as this would be expected to progress to T1D more frequently than older children with single IA [2] as reported in analyses of rates of progression according to the number of islet autoantibodies [22,23].”
BackgroundType 1 diabetes and inborn errors of immunity: Complete strangers or 2 sides of the same coin?
Mancuso, G., Genzano, C. B., Fierabracci, A., & Fousteri, G. (2023) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2023.03.026 · Cited by 14
Liu, J., Bian, L., Li, J., Chen, Y., Chen, H., Gu, Y., Ma, B., Gu, W., Xu, X., Shi, Y., et al. (2016) · Science China Life Sciences · doi:10.1007/s11427-016-5052-3 · Cited by 13
“The increase of the persistent islet-specific autoantibodies was positively correlated to the probability of developing disease (Bingley et al., 2006; Gale, 1994; Orban et al., 2009; Siljander et al., 2009; Verge et al., 1996; Ziegler, 2004).”
BackgroundSelf-citationBoudiaf, A., Bouziane, D., Smara, M., Meddour, Y., Haffaf, E. M., Oudjit, B., Mamouzi, S. C., & Bouguerra, S. A. (2018) · Current Research in Translational Medicine · doi:10.1016/j.retram.2018.01.003 · Cited by 14
A simplified method to assess affinity of insulin autoantibodies
Achenbach, P., Guo, L., Gick, C., Adler, K., Krause, S., Bonifacio, E. E., Colman, P. G., & Ziegler, A. (2010) · Clinical Immunology · doi:10.1016/j.clim.2010.09.002 · Cited by 13
Etiopathogenesis of Insulin Autoimmunity
Kanatsuna, N., Papadopoulos, G. K., Moustakas, A. K., & Lernmark, Å. (2012) · Anatomy Research International · doi:10.1155/2012/457546 · Cited by 14
“However, most authors suggest that the number of islet autoantibodies is the strongest predictor of clinical onset of T1D [170].”
BackgroundMethodInfluentialPrevention of type 1 diabetes mellitus using a novel vaccine
Orban, T., & Kis, J. T. (2010) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018810390546 · Cited by 11
“%) in the oral insulin arm, than in the placebo arm (10.4%, p¼ 0.015) [Orban et al. 2009; Barker et al. 2007; Skyler et al. 2005; Schatz and Bingley, 2001].”
BackgroundSelf-citationIsmail, H. M., Cuthbertson, D. D., Gitelman, S. E., Skyler, J. S., Steck, A. K., Rodriguez, H., Atkinson, M. A., Nathan, B. M., REDONDO, M. J., Herold, K. C., et al. (2022) · Diabetes Care · doi:10.2337/dc22-0167 · Cited by 11
Self-citationMetabolic Abnormalities in the Pathogenesis of Type 1 Diabetes
Zheng, S., & Mathews, C. E. (2014) · Current Diabetes Reports · doi:10.1007/s11892-014-0519-8 · Cited by 11
the DiAPREV-IT study group, Larsson, H. E., Larsson, C., & Lernmark, Å. (2014) · Acta Diabetologica · doi:10.1007/s00592-014-0680-1 · Cited by 11
Antigen-Specific Therapy Against Type 1 Diabetes: Mechanisms and Perspectives
Wan, X., & Zaghouani, H. (2014) · Immunotherapy · doi:10.2217/imt.13.172 · Cited by 11
Diabetes Melito tipo 1 autoimune: aspectos imunológicos - doi: 10.5102/ucs.v14i1.3406
de Sousa, A. A., Albernaz, A. C., & Sobrinho, H. M. D. R. (2016) · Universitas Ciências da Saúde · doi:10.5102/ucs.v14i1.3406 · Cited by 16
Emerging Approaches in Surveillance of Type 1 Diabetes
Saydah, S., & Imperatore, G. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-1033-1 · Cited by 11
“gov 1 Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Division of Diabetes Translation, 4770 Bufford Highway, MS F-75, Atlanta, GA 30341, USA Current Diabetes Reports (2018) 18: 61 https://doi.”
InfluentialSerbis, A., Kantza, E., Siomou, E. C., Galli‐Τsinopoulou, A., Kanaka‐Gantenbein, C., & Tigas, S. K. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms251910501 · Cited by 12
“When two or more of these are positive, a diagnosis of T1D can be established, thus precluding the need for genetic testing [83,84].”
BackgroundNeuropeptide Y is a minor autoantigen in newly diagnosed type 1 diabetes patients
Skärstrand, H., Vaziri‐Sani, F., Delli, A. J., Törn, C., Larsson, H. E., Ivarsson, S. A., Agardh, D., Lernmark, Å., & the Skåne study group (2014) · Pediatric Diabetes · doi:10.1111/pedi.12222 · Cited by 10
“This notion is supported because multiple studies have shown that the larger the number of autoantibodies the greater the risk for progression to clinical diagnosis of T1D (20, 21).”
Tiberti, C., Montuori, M., Trovato, C. M., Panimolle, F., Filardi, T., Valitutti, F., Lenzi, A., Cucchiara, S., & Morano, S. (2020) · Pediatric Diabetes · doi:10.1111/pedi.13054 · Cited by 11
Exocrine pancreas function is impaired in adult relatives of patients with type 1 diabetes
Giovenzana, A., Vecchio, F., Cugnata, F., Nonis, A., Mandelli, A., Stabilini, A., Mazzi, B. A., Pellegrin, M. D., Laurenzi, A., Bonfanti, R., et al. (2021) · Acta Diabetologica · doi:10.1007/s00592-021-01819-2 · Cited by 10
Oettingen, J. E. V., Wolfsdorf, J. I., Feldman, H. A., & Rhodes, E. T. (2015) · Pediatric Diabetes · doi:10.1111/pedi.12304 · Cited by 10
“Before 1 January 2009, IAA was measured in the Clinical Immunology Laboratory at the Joslin Diabetes Center (Boston, MA, USA) using a competitive insulin antibody assay (13); GAD and IA2 were measured using quantitative radioimmunoassay (14).”
MethodHave we pushed the needle for treatment of Type 1 diabetes?
Naushad, N., Perdigoto, A. L., Rui, J., & Herold, K. C. (2017) · Current Opinion in Immunology · doi:10.1016/j.coi.2017.09.004 · Cited by 9
Risk Factors of Type 1 Diabetes Mellitus
(2022) · Biomedical Science and Clinical Research · doi:10.33140/bscr.01.01.05 · Cited by 9
Clinical and experimental treatment of type 1 diabetes
Long, S. A., & Buckner, J. H. (2022) · Clinical & Experimental Immunology · doi:10.1093/cei/uxac077 · Cited by 9
Atkinson, M. A. (2016) · Elsevier eBooks · doi:10.1016/b978-0-323-29738-7.00032-0 · Cited by 20
Johnson, R. K., Tamura, R., Frank, N., Uusitalo, U. M., Yang, J., Niinistö, S., Aronsson, C. A., Ziegler, A., Hagopian, W., Rewers, M., et al. (2021) · Diabetologia · doi:10.1007/s00125-021-05446-y · Cited by 8
Self-citationBanach, M., Harley, I. T. W., Getahun, A., & Cambier, J. C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.961209 · Cited by 8
The role of fatty acid metabolism on B cells and B cell-related autoimmune diseases
Gong, Y., Xu, R., Gao, G., Li, S., & Liu, Y. (2025) · Inflammation Research · doi:10.1007/s00011-025-02042-3 · Cited by 7
“Although islet-reactive T cells are traditionally considered the primary effectors of pancreatic β-cell destruction in T1DM, B cells also play a critical role in antigen presentation, cytokine production, and autoantibody generation [166, 167].”
Greenbaum, C. J., Nepom, G. T., Heickman, L. K. W., Wherrett, D. K., DiMeglio, L. A., Herold, K. C., & Krischer, J. P. (2024) · Diabetes · doi:10.2337/dbi24-0020 · Cited by 8
Self-citationKinney, M., You, L., Sims, E. K., Wherrett, D. K., Schatz, D., Lord, S. M., Krischer, J. P., Russell, W. E., Gottlieb, P. A., Libman, I. M., et al. (2023) · Journal of the Endocrine Society · doi:10.1210/jendso/bvad003 · Cited by 6
Self-citationFilchtinski, D., Kayser, J., Ettner, V., Holz, S., Kristensen, B. W., Schulte-Pelkum, J., Wilhelm, I., & Fiedler, R. (2025) · Journal of Immunological Methods · doi:10.1016/j.jim.2025.113885 · Cited by 7
Sanyal, D., Batabyal, S., Maity, S., & Chatterjee, S. (2019) · Clinical Diabetology · doi:10.5603/dk.2019.0005 · Cited by 6
Incorporating Type 1 Diabetes Prevention Into Clinical Practice
Gregory, J. M., Lilley, J. S., Misfeldt, A. A., Buscariollo, D. L., Russell, W. E., & Moore, D. J. (2010) · Clinical Diabetes · doi:10.2337/diaclin.28.2.61 · Cited by 6
Metadata
- Authors
- Orban, T., Sosenko, J. M., Cuthbertson, D., Krischer, J. P., Skyler, J. S., Jackson, R., Yu, L., Palmer, J. P., Schatz, D., Eisenbarth, G., & for the Diabetes Prevention Trial–Type 1 Study Group
- Affiliations
- Joslin Diabetes Center (US)
- University of Miami (US)
- University of South Florida (US)
- Barbara Davis Center for Childhood Diabetes, Denver, Colorado;
- University of Washington (US)
- University of Florida Health (US)
- Corresponding author
- Sosenko, Jay M.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2009-09-09
- Volume
- 32
- Issue
- 12
- Pages
- 2269-2274
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC2782989
- OpenAlex
- W2164736991
- Cited by
- 260
- References
- 31
- Citations by year
- 2026: 2 · 2025: 10 · 2024: 9 · 2023: 8 · 2022: 18 · 2021: 17 · 2020: 9 · 2019: 18 · 2018: 11 · 2017: 14 · 2016: 20 · 2015: 26 · 2014: 24 · 2013: 24 · 2012: 25
- FWCI
- 9.69
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- Joslin Diabetes Center
- National Institute of Diabetes and Digestive and Kidney Diseases (UC4DK117009)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Keywords
- type 1 diabetes, islet autoantibodies, GAD65 antibodies, autoantibody titers, diabetes prediction, prevention trials
- MeSH terms
- Autoantibodies, Diabetes Mellitus, Type 1, Glutamate Decarboxylase, Humans, Islets of Langerhans, Predictive Value of Tests, Prospective Studies, Surveys and Questionnaires, Cohort Studies, Receptor-Like Protein Tyrosine Phosphatases, Class 8
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.